Quarterly highlights include:
- Net sales increased 1% to $511.7 million, or 3% on a constant currency basis, compared to the prior year period.
- Operating income of $25.3 million compared to an operating loss of $2.6 million in the prior year period.
- Net income of $3.7 million compared to a net loss of $7.3 million in the prior year period.
- Adjusted EBITDA of $62.2 million compared to $49.4 million in the prior year period.
- Earnings per diluted share ("EPS") of $0.04 compared to a loss of $0.07 in the prior year period.
- Repurchased 0.1 million shares, or 0.1% of the outstanding common stock, at an average price of $24.97 per share.
- Net cash provided by continuing operations of $92.8 million compared to $21.0 million in prior year period.
Related: Hain Completes Sale of Danival Sprouts Sees 16% Sales Increase in Second Quarter 2020 CV Sciences Reports Q2 Results
Results of fiscal year 2020 include:- Net sales decreased 2% to $2,053.9 million compared to the prior year.
- When adjusted for Foreign Exchange, Divestitures, discontinued brands and "SKU" rationalization3, net sales increased 3% compared to the prior year.
- Gross margin of 22.7%, a 374 basis point increase over the prior year.
- Operating income of $56.0 million compared to operating loss of $32.5 million in the prior year.
- Net income of $25.6 million compared to net loss of $53.4 million in the prior year.
- Adjusted EBITDA of $200.0 million compared to $165.1 million in the prior year.
- EPS of $0.25 compared to a loss of $0.51 in the prior year.
- Repurchased 2.6 million shares, or 2.4% of the outstanding common stock, at an average price of $23.59 per share.